IDH inhibitors in acute myeloid leukemia and myelodysplastic syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):556-558.NO ABSTRACTPMID:34495017 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Eytan M Stein Source Type: research

Bleeding complications with Bruton tyrosine kinase inhibitors
Clin Adv Hematol Oncol. 2021 Sep;19(9):559-561.NO ABSTRACTPMID:34495018 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Thomas G DeLoughery Source Type: research

A patient's perspective on long-term toxicities associated with cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):566-568.NO ABSTRACTPMID:34495019 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Patricia A Spears Source Type: research

The use of neoadjuvant therapy to further personalize breast cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):569-572.NO ABSTRACTPMID:34495020 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Laura J Esserman Source Type: research

How we treat mycosis fungoides and S ézary syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):573-581.NO ABSTRACTPMID:34495021 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Niloufer Khan Sarah J Noor Steven Horwitz Source Type: research

Management of well-differentiated neuroendocrine tumors
Clin Adv Hematol Oncol. 2021 Sep;19(9):582-593.ABSTRACTNeuroendocrine tumors (NETs) are a heterogeneous group of epithelial neoplasms with predominantly neural and endocrine differentiation that have the ability to produce peptide hormones and other biologically active substances. The histologic characterization of NETs based on differentiation and grading is crucial to determining prognosis and treatment. Surgery still offers the best chance of cure for patients with NETs, and tumor resection is the preferred approach when possible. For locally advanced or metastatic disease, approaches to treatment can vary widely depend...
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Sri Harsha Tella Jason S Starr Anuhya Kommalapati Mohamad Bassam Sonbol Thorvardur R Halfdanarson Source Type: research

IDH inhibitors in acute myeloid leukemia and myelodysplastic syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):556-558.NO ABSTRACTPMID:34495017 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Eytan M Stein Source Type: research

Bleeding complications with Bruton tyrosine kinase inhibitors
Clin Adv Hematol Oncol. 2021 Sep;19(9):559-561.NO ABSTRACTPMID:34495018 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Thomas G DeLoughery Source Type: research

A patient's perspective on long-term toxicities associated with cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):566-568.NO ABSTRACTPMID:34495019 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Patricia A Spears Source Type: research

The use of neoadjuvant therapy to further personalize breast cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):569-572.NO ABSTRACTPMID:34495020 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Laura J Esserman Source Type: research

How we treat mycosis fungoides and S ézary syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):573-581.NO ABSTRACTPMID:34495021 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Niloufer Khan Sarah J Noor Steven Horwitz Source Type: research

Management of well-differentiated neuroendocrine tumors
Clin Adv Hematol Oncol. 2021 Sep;19(9):582-593.ABSTRACTNeuroendocrine tumors (NETs) are a heterogeneous group of epithelial neoplasms with predominantly neural and endocrine differentiation that have the ability to produce peptide hormones and other biologically active substances. The histologic characterization of NETs based on differentiation and grading is crucial to determining prognosis and treatment. Surgery still offers the best chance of cure for patients with NETs, and tumor resection is the preferred approach when possible. For locally advanced or metastatic disease, approaches to treatment can vary widely depend...
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Sri Harsha Tella Jason S Starr Anuhya Kommalapati Mohamad Bassam Sonbol Thorvardur R Halfdanarson Source Type: research

IDH inhibitors in acute myeloid leukemia and myelodysplastic syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):556-558.NO ABSTRACTPMID:34495017 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Eytan M Stein Source Type: research

Bleeding complications with Bruton tyrosine kinase inhibitors
Clin Adv Hematol Oncol. 2021 Sep;19(9):559-561.NO ABSTRACTPMID:34495018 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Thomas G DeLoughery Source Type: research

A patient's perspective on long-term toxicities associated with cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):566-568.NO ABSTRACTPMID:34495019 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Patricia A Spears Source Type: research

The use of neoadjuvant therapy to further personalize breast cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):569-572.NO ABSTRACTPMID:34495020 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Laura J Esserman Source Type: research

How we treat mycosis fungoides and S ézary syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):573-581.NO ABSTRACTPMID:34495021 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Niloufer Khan Sarah J Noor Steven Horwitz Source Type: research

Management of well-differentiated neuroendocrine tumors
Clin Adv Hematol Oncol. 2021 Sep;19(9):582-593.ABSTRACTNeuroendocrine tumors (NETs) are a heterogeneous group of epithelial neoplasms with predominantly neural and endocrine differentiation that have the ability to produce peptide hormones and other biologically active substances. The histologic characterization of NETs based on differentiation and grading is crucial to determining prognosis and treatment. Surgery still offers the best chance of cure for patients with NETs, and tumor resection is the preferred approach when possible. For locally advanced or metastatic disease, approaches to treatment can vary widely depend...
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Sri Harsha Tella Jason S Starr Anuhya Kommalapati Mohamad Bassam Sonbol Thorvardur R Halfdanarson Source Type: research

IDH inhibitors in acute myeloid leukemia and myelodysplastic syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):556-558.NO ABSTRACTPMID:34495017 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Eytan M Stein Source Type: research

Bleeding complications with Bruton tyrosine kinase inhibitors
Clin Adv Hematol Oncol. 2021 Sep;19(9):559-561.NO ABSTRACTPMID:34495018 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Thomas G DeLoughery Source Type: research

A patient's perspective on long-term toxicities associated with cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):566-568.NO ABSTRACTPMID:34495019 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Patricia A Spears Source Type: research

The use of neoadjuvant therapy to further personalize breast cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):569-572.NO ABSTRACTPMID:34495020 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Laura J Esserman Source Type: research

How we treat mycosis fungoides and S ézary syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):573-581.NO ABSTRACTPMID:34495021 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Niloufer Khan Sarah J Noor Steven Horwitz Source Type: research

Management of well-differentiated neuroendocrine tumors
Clin Adv Hematol Oncol. 2021 Sep;19(9):582-593.ABSTRACTNeuroendocrine tumors (NETs) are a heterogeneous group of epithelial neoplasms with predominantly neural and endocrine differentiation that have the ability to produce peptide hormones and other biologically active substances. The histologic characterization of NETs based on differentiation and grading is crucial to determining prognosis and treatment. Surgery still offers the best chance of cure for patients with NETs, and tumor resection is the preferred approach when possible. For locally advanced or metastatic disease, approaches to treatment can vary widely depend...
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Sri Harsha Tella Jason S Starr Anuhya Kommalapati Mohamad Bassam Sonbol Thorvardur R Halfdanarson Source Type: research

IDH inhibitors in acute myeloid leukemia and myelodysplastic syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):556-558.NO ABSTRACTPMID:34495017 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Eytan M Stein Source Type: research

Bleeding complications with Bruton tyrosine kinase inhibitors
Clin Adv Hematol Oncol. 2021 Sep;19(9):559-561.NO ABSTRACTPMID:34495018 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Thomas G DeLoughery Source Type: research

A patient's perspective on long-term toxicities associated with cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):566-568.NO ABSTRACTPMID:34495019 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Patricia A Spears Source Type: research

The use of neoadjuvant therapy to further personalize breast cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):569-572.NO ABSTRACTPMID:34495020 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Laura J Esserman Source Type: research

How we treat mycosis fungoides and S ézary syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):573-581.NO ABSTRACTPMID:34495021 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Niloufer Khan Sarah J Noor Steven Horwitz Source Type: research

Management of well-differentiated neuroendocrine tumors
Clin Adv Hematol Oncol. 2021 Sep;19(9):582-593.ABSTRACTNeuroendocrine tumors (NETs) are a heterogeneous group of epithelial neoplasms with predominantly neural and endocrine differentiation that have the ability to produce peptide hormones and other biologically active substances. The histologic characterization of NETs based on differentiation and grading is crucial to determining prognosis and treatment. Surgery still offers the best chance of cure for patients with NETs, and tumor resection is the preferred approach when possible. For locally advanced or metastatic disease, approaches to treatment can vary widely depend...
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Sri Harsha Tella Jason S Starr Anuhya Kommalapati Mohamad Bassam Sonbol Thorvardur R Halfdanarson Source Type: research

IDH inhibitors in acute myeloid leukemia and myelodysplastic syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):556-558.NO ABSTRACTPMID:34495017 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Eytan M Stein Source Type: research

Bleeding complications with Bruton tyrosine kinase inhibitors
Clin Adv Hematol Oncol. 2021 Sep;19(9):559-561.NO ABSTRACTPMID:34495018 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Thomas G DeLoughery Source Type: research

A patient's perspective on long-term toxicities associated with cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):566-568.NO ABSTRACTPMID:34495019 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Patricia A Spears Source Type: research

The use of neoadjuvant therapy to further personalize breast cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):569-572.NO ABSTRACTPMID:34495020 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Laura J Esserman Source Type: research

How we treat mycosis fungoides and S ézary syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):573-581.NO ABSTRACTPMID:34495021 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Niloufer Khan Sarah J Noor Steven Horwitz Source Type: research

Management of well-differentiated neuroendocrine tumors
Clin Adv Hematol Oncol. 2021 Sep;19(9):582-593.ABSTRACTNeuroendocrine tumors (NETs) are a heterogeneous group of epithelial neoplasms with predominantly neural and endocrine differentiation that have the ability to produce peptide hormones and other biologically active substances. The histologic characterization of NETs based on differentiation and grading is crucial to determining prognosis and treatment. Surgery still offers the best chance of cure for patients with NETs, and tumor resection is the preferred approach when possible. For locally advanced or metastatic disease, approaches to treatment can vary widely depend...
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Sri Harsha Tella Jason S Starr Anuhya Kommalapati Mohamad Bassam Sonbol Thorvardur R Halfdanarson Source Type: research

IDH inhibitors in acute myeloid leukemia and myelodysplastic syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):556-558.NO ABSTRACTPMID:34495017 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Eytan M Stein Source Type: research

Bleeding complications with Bruton tyrosine kinase inhibitors
Clin Adv Hematol Oncol. 2021 Sep;19(9):559-561.NO ABSTRACTPMID:34495018 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Thomas G DeLoughery Source Type: research

A patient's perspective on long-term toxicities associated with cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):566-568.NO ABSTRACTPMID:34495019 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Patricia A Spears Source Type: research

The use of neoadjuvant therapy to further personalize breast cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):569-572.NO ABSTRACTPMID:34495020 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Laura J Esserman Source Type: research

How we treat mycosis fungoides and S ézary syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):573-581.NO ABSTRACTPMID:34495021 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Niloufer Khan Sarah J Noor Steven Horwitz Source Type: research

Management of well-differentiated neuroendocrine tumors
Clin Adv Hematol Oncol. 2021 Sep;19(9):582-593.ABSTRACTNeuroendocrine tumors (NETs) are a heterogeneous group of epithelial neoplasms with predominantly neural and endocrine differentiation that have the ability to produce peptide hormones and other biologically active substances. The histologic characterization of NETs based on differentiation and grading is crucial to determining prognosis and treatment. Surgery still offers the best chance of cure for patients with NETs, and tumor resection is the preferred approach when possible. For locally advanced or metastatic disease, approaches to treatment can vary widely depend...
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Sri Harsha Tella Jason S Starr Anuhya Kommalapati Mohamad Bassam Sonbol Thorvardur R Halfdanarson Source Type: research

IDH inhibitors in acute myeloid leukemia and myelodysplastic syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):556-558.NO ABSTRACTPMID:34495017 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Eytan M Stein Source Type: research

Bleeding complications with Bruton tyrosine kinase inhibitors
Clin Adv Hematol Oncol. 2021 Sep;19(9):559-561.NO ABSTRACTPMID:34495018 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Thomas G DeLoughery Source Type: research

A patient's perspective on long-term toxicities associated with cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):566-568.NO ABSTRACTPMID:34495019 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Patricia A Spears Source Type: research

The use of neoadjuvant therapy to further personalize breast cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):569-572.NO ABSTRACTPMID:34495020 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Laura J Esserman Source Type: research

How we treat mycosis fungoides and S ézary syndrome
Clin Adv Hematol Oncol. 2021 Sep;19(9):573-581.NO ABSTRACTPMID:34495021 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Niloufer Khan Sarah J Noor Steven Horwitz Source Type: research

Management of well-differentiated neuroendocrine tumors
Clin Adv Hematol Oncol. 2021 Sep;19(9):582-593.ABSTRACTNeuroendocrine tumors (NETs) are a heterogeneous group of epithelial neoplasms with predominantly neural and endocrine differentiation that have the ability to produce peptide hormones and other biologically active substances. The histologic characterization of NETs based on differentiation and grading is crucial to determining prognosis and treatment. Surgery still offers the best chance of cure for patients with NETs, and tumor resection is the preferred approach when possible. For locally advanced or metastatic disease, approaches to treatment can vary widely depend...
Source: Clinical Advances in Hematology and Oncology - September 8, 2021 Category: Cancer & Oncology Authors: Sri Harsha Tella Jason S Starr Anuhya Kommalapati Mohamad Bassam Sonbol Thorvardur R Halfdanarson Source Type: research

PSMA-targeted radiotherapy in metastatic castration-resistant prostate cancer
Clin Adv Hematol Oncol. 2021 Aug;19(8):494-496.NO ABSTRACTPMID:34411067 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 19, 2021 Category: Cancer & Oncology Authors: A Oliver Sartor Source Type: research

HIPEC in ovarian cancer: hip or hype?
Clin Adv Hematol Oncol. 2021 Aug;19(8):497-499.NO ABSTRACTPMID:34411068 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 19, 2021 Category: Cancer & Oncology Authors: Leslie M Randall Source Type: research